Aurinia Q1 revenue $62.5M (+24% YoY); net income $23.3M vs loss of $10.7M; LUPKYNIS sales up 25%

Aurinia Pharmaceuticals Inc.

2025-Q1 EPS reported $0.16 revenue$62,465,000

Total revenue $62.5M, up 24% YoY; net product sales of LUPKYNIS were $60.0M (+25% YoY).
Net income $23.3M vs net loss $(10.7)M in Q1 2024; cash flow from operations $1.3M ($12.4M ex-restructuring).
Cash and investments $312.9M; repurchased 5.8M shares for $47.4M in Q1.
Full-year 2025 revenue guidance reaffirmed: $250-$260M; net product sales guidance $240-$250M.
Initial Phase 1 results for dual BAFF/APRIL inhibitor AUR200 expected later this quarter.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.